PPD, Inc. (Nasdaq:PPD), was recognized for leadership at the 13th annual Vaccine Industry Excellence (ViE) Awards during the 2020 World Vaccine Congress.
The ViE awards celebrate the outstanding achievements of organizations and individuals setting high standards of excellence and advocacy in the vaccine industry. This year, PPD was named the winner of the Best Central Laboratory award.
With more than 25 years of vaccine development experience for both government and commercial customers, PPD provides integrated clinical and laboratory vaccine expertise and global resources to advance its customers’ vaccine programs. During the past five years, PPD has supported more than 200 vaccine trials globally.
PPD, with a global team of therapeutic specialists, is fully immersed in the latest advances in the field of vaccine development, with expertise in trial design, data analytics, manufacturing, project management, logistics, laboratory testing, pharmacovigilance and regulatory requirements.
PPD offers full-service vaccine capabilities and distinctive expertise across a wide spectrum of vaccine programs, including early-phase vaccine development; field-efficacy studies in selected geographies and targeted populations; rapid site startup and capacity to support large vaccine trials; cold-chain management; serology specimen chain-of-custody and unique logistics of vaccine studies; and real-time data access to facilitate data analytics and safety trend analysis.
“Now more than ever, as we face the global COVID-19 pandemic, we are accelerating our efforts surrounding the development of vaccines,” said Christopher Fikry, M.D., executive vice president of PPD® Laboratories. “We provide innovative solutions to expedite clinical trials to help our customers develop safe and effective vaccines. In these challenging times, our mission has never been clearer – helping deliver life-changing therapies to people in need.”
PPD Laboratories provides comprehensive central and specialized vaccine lab support for all trial phases, including safety, efficacy and immunogenicity testing, as well as development consulting services. Optimized global services include high-capacity biorepository storage and customized kit and kit-less options to reduce storage space needs for high-throughput vaccine trials. Additionally, PPD’s award-winning Preclarus® Investigator Site Portal provides a clean, real-time chain of custody to the central lab industry. PPD Laboratories also provides comprehensive bioanalytical, biomarker and good manufacturing practice (GMP) laboratory services.
PPD Laboratories’ test portfolio includes more than 1,500 assays, along with a variety of drug characterization methods and bioanalytical analysis tools. PPD has broad experience across viral and bacterial agents, as well as extensive expertise with multiplexed functional assays. PPD Laboratories has aided 15 vaccine programs approved by the U.S. Food and Drug Administration and is currently supporting 38 preventive and therapeutic vaccines and 46 drug trials being assessed for use against COVID-19.
In addition, through PPD’s Accelerated Enrollment Solutions business, the Optimal Vaccine Centers of Excellence offer one of the world’s largest integrated networks of vaccine clinical research sites, spanning 77 geographically diverse locations across 12 countries, with 34 sites in the United States. For more than 10 years, Optimal Research sites have specialized in conducting clinical trials for vaccine and infectious disease (ID) products, including over 600 vaccine and ID studies in recent years.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.